Biotech Bay
Filter News
Found 85,350 articles
-
QT Imaging Announces Second Blinded Screening Trial Finding Its Technology Similarly Effective as Digital Breast Tomosynthesis
4/16/2024
QT Imaging Holdings, Inc. is proud to announce positive data regarding the diagnostic performance of QTI’s Breast Acoustic CT TM Scans for mass detection from its second blinded multi-reader multi-case study.
-
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
4/16/2024
Jaguar Health, Inc. today announced that it has signed an exclusive 5-year in-license agreement with United Kingdom-based Venture Life Group PLC.
-
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
4/16/2024
Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million.
-
PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance
4/16/2024
PacBio today announced preliminary, unaudited revenue for the quarter ended March 31, 2024.
-
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - April 16, 2024
4/16/2024
Annexon, Inc. announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.
-
Biolog Expands the Odin Family, and Access to Cellular Characterization, With the Launch of Odin VIII
4/16/2024
Biolog, Inc., a leading provider of cell-based microbial identification and phenotypic and metabolic profiling products and services, announced the launch of OdinTM VIII system, the newest member of its Odin family of instruments.
-
Jaya Biosciences Presents Updated Preclinical Data in Alzheimer’s Disease at the 45th SIMD Annual Meeting
4/16/2024
Jaya Biosciences, Inc. reported preclinical data at the 45th Annual Meeting of the Society for Inherited Metabolic Disorders, a leading research conference on inherited metabolic diseases, including lysosomal diseases.
-
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring
4/16/2024
Glucotrack, Inc., a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it is expanding its glucose monitoring technology to include measuring glucose in the epidural space.
-
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
4/16/2024
Boehringer Ingelheim announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.
-
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
4/16/2024
CareDx, Inc. has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company’s Board of Directors, effective April 15, 2024.
-
Avirmax Inc. to Make Scientific Presentations at ASGCT in Baltimore
4/16/2024
Avirmax Inc., will make two scientific presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore between May 7th and 11th, 2024.
-
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
4/16/2024
Veracyte, Inc today announced that nine abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2024, the annual meeting of the American Urological Association, taking place May 3-6 in San Antonio.
-
Excision BioTherapeutics Announces Oral Presentation of HSV-1 Keratitis Data at CRISPRMED24 Conference on April 24 2024
4/16/2024
Excision BioTherapeutics, Inc. today announced that it will make an oral presentation on April 24, 2024, at CRISPRMED24, the first CRISPR Medicine Conference, which is being held from April 23-25 in Copenhagen, Denmark.
-
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
4/16/2024
Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2024 financial results will be released on Tuesday, April 30, 2024 after the markets close.
-
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
4/16/2024
Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT.
-
Leading Global Biotechnology Company Selects ValGenesis iRisk to Advance Its Pipeline of Critical Drug Therapies
4/16/2024
ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems (VLMS), today announced that a leading global biotechnology company selected ValGenesis iRisk to digitalize the quality risk management processes across its manufacturing sites.
-
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4/16/2024
Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which includes 1,750,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock.
-
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
4/15/2024
Corcept Therapeutics Incorporated today announced completion of enrollment in DAZALS, a randomized, double-blind, placebo-controlled Phase 2 trial of its proprietary selective cortisol modulator dazucorilant in patients with amyotrophic lateral sclerosis (ALS).
-
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
4/15/2024
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the completion of the dose escalation portion of the Phase 1b trial of ORIC-114 in patients with advanced solid tumors with EGFR and HER2 exon 20 alterations or HER2 amplifications.
-
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
4/15/2024
Ultragenyx Pharmaceutical Inc. announced new data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome.